It looks like you're offline.
Open Library logo
additional options menu
⚠ Urge publishers to restore access to 500,000 removed library books: Sign Letter - Learn More

MARC Record from Library of Congress

Record ID marc_loc_updates/v39.i52.records.utf8:54429052:2300
Source Library of Congress
Download Link /show-records/marc_loc_updates/v39.i52.records.utf8:54429052:2300?format=raw

LEADER: 02300cam a22003378a 4500
001 2011030483
003 DLC
005 20111220182748.0
008 110719s2011 enk b 001 0 eng
010 $a 2011030483
020 $a9780521766272 (hardback)
035 $a(DNLM)101564947
040 $aDNLM/DLC$cDLC
042 $apcc
060 10 $aWL 360
082 00 $a616.8/34$223
245 00 $aMultiple sclerosis therapeutics /$cedited by Jeffrey A. Cohen, Richard A. Rudick.
250 $a4th ed.
260 $aCambridge :$bCambridge University Press,$c2011.
263 $a1110
300 $ap. ;$ccm.
504 $aIncludes bibliographical references and index.
505 8 $aMachine generated contents note: Part I. Introduction; Part II. Clinical Trial Methodology; Part III. Clinical Trials of Multiple Sclerosis Therapies; Part IV. Therapy in Clinical Practice.
520 $a"This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors"--Provided by publisher.
650 12 $aMultiple Sclerosis$xtherapy.
650 22 $aClinical Trials as Topic$xmethods.
650 22 $aMagnetic Resonance Imaging.
650 22 $aMultiple Sclerosis$xpathology.
650 22 $aOutcome Assessment (Health Care)
700 1 $aCohen, Jeffrey A.$q(Jeffrey Alan),$d1954-
700 1 $aRudick, Richard A.